Comparative Pharmacology
Head-to-head clinical analysis: BRISTACYCLINE versus DECLOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTACYCLINE versus DECLOMYCIN.
BRISTACYCLINE vs DECLOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRISTACYCLINE is a tetracycline antibiotic that reversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
250 mg orally every 6 hours for 7-14 days.
150 mg orally every 6 hours or 300 mg orally every 12 hours.
None Documented
None Documented
6-12 hours (terminal). In renal impairment, half-life extends up to 24-48 hours; dose adjustment required for CrCl <30 mL/min.
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
Renal (40-60% unchanged), fecal (20-30%, primarily as inactive metabolites). Biliary excretion contributes minimally (<5%).
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic